Karenann Terrell appointed Chief Digital & Technology Officer, GSK

Issued: London UK

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Karenann Terrell has been appointed Chief Digital & Technology Officer with a company-wide remit to transform how new technologies are used to improve performance across the Group. Karenann will join GSK on 4 September and will be a member of the Corporate Executive Team (CET).

In this new role for GSK, Karenann will be responsible for developing GSK’s digital, data and analytics strategy. She will work with a wide range of partners from inside and outside the healthcare sector to bring new technologies to GSK, enhancing areas such as clinical trials and drug development; improving how we interact with HCPs, customers and consumers and making internal processes more efficient.

Karenann’s previous role was Chief Information Officer for Walmart, where she led a multi-year effort to transform Walmart in the use of data, analytics and digital engagement with its customers.

Emma Walmsley, Chief Executive Officer, GSK, said: “The impact of technology on the healthcare industry is accelerating and requires us to rethink our approach. As a member of the Executive Team, Karenann will have the scope to think radically about how we can exploit the latest opportunities and ultimately improve our business performance.”

Karenann has lived and worked in the US, Asia and Europe. Prior to Walmart she was at Baxter International Inc., where she was Chief Information Officer and before that Daimler Chrysler Corporation. Karenann began her career in 1986 in General Motors and held various roles in manufacturing, engineering and brand management, end her career there as Director of e-Vehicles. She possesses graduate and post-graduate degrees in Engineering.

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com/about-us.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2016.